Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antibiotic
    (1)
  • Apoptosis
    (3)
  • Caspase
    (2)
  • Dehydrogenase
    (1)
  • ERK
    (2)
  • Endogenous Metabolite
    (2)
  • HDAC
    (1)
  • Lipoxygenase
    (1)
  • Monoamine Oxidase
    (1)
  • Others
    (11)
Filter
Search Result
Results for "

cirrhosis

" in TargetMol Product Catalog
  • Inhibitor Products
    26
    TargetMol | Activity
  • Recombinant Protein
    9
    TargetMol | inventory
  • Natural Products
    3
    TargetMol | natural
  • Isotope products
    3
    TargetMol | composition
  • Peptides Products
    2
    TargetMol | Activity
  • Compound Libraries
    1
    TargetMol | inventory
  • Inhibitory Antibodies
    1
    TargetMol | natural
Odevixibat
T16376501692-44-0
Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model.
  • $52
In Stock
Size
QTY
Malotilate
T657659937-28-9
Malotilate (Kantec) is a medicine used for the therapy of liver cirrhosis.
  • $45
In Stock
Size
QTY
Sodium Glucuronic Acid
T36117182-77-6
Sodium Glucuronic Acid (4-FLUOROCINNAMONITRILE) is used in the treatment of hepatitis and liver cirrhosis.
  • $48
In Stock
Size
QTY
Cefetamet sodium
T3078765243-25-6In house
Cefetamet sodium (Ro 15-8074/001) is an orally available cephalosporin antibiotic with antimicrobial activity and is used to study cirrhosis of the liver and lung infections.
  • $293 TargetMol
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Selvigaltin
T637511978336-95-6In house
Selvigaltin (GB1211) is a Gal-3 inhibitor with potential anticancer activity. Selvigaltin is used in the study of cirrhosis and cancer.
  • $289
In Stock
Size
QTY
Sinapinic Acid
T3753530-59-6
Sinapinic Acid (Synapoic acid) protects the rat liver from CCl4-induced inflammation, most likely by acting as a free radical scavenger and modulator of NF-κB p65 activation and proinflammatory cytokine expression. Sinapic acid with antioxidant role protects cardiac cells and its functions from I/R induced oxidative stress. Sinapic acid is a potentially useful agent for the protection against liver fibrosis and cirrhosis. Sinapic acid prevents the alterations in the levels of lipids and lipoproteins by virtue of its anti-lipidaemic effect in isoproterenol induced myocardial infarcted rats. Sinapic acid ameliorates hyperglycemia through PLC-PKC signals to enhance the glucose utilization in diabetic rats.
  • $29
In Stock
Size
QTY
TargetMol | Citations Cited
Tauroursodeoxycholate sodium
T699335807-85-3
Tauroursodeoxycholate sodium (TUDC) is an endoplasmic reticulum (ER) stress inhibitor, used for the treatment of gallstones and liver cirrhosis.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
S-Adenosyl-L-methionine
T747529908-03-0
S-Adenosyl-L-methionine (Ademetionine) is an intermediate metabolite of methionine,for treatment of primary biliary cirrhosis and major depressive disorder.
  • $369
Inquiry
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Tauroursodeoxycholate
T253214605-22-2
Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
  • $50
In Stock
Size
QTY
TargetMol | Citations Cited
CT52923
T60226205256-55-9
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Simtuzumab
T767001318075-13-6
Simtuzumab is a monoclonal antibody against lysyl oxidase-like protein 2 (LOXL2). Simtuzumab can be used to treat primary sclerosing cholangitis (PSC) and is not effective in patients with bridging fibrosis or compensatory cirrhosis caused by non-alcoholic steatohepatitis.
  • $222
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Taurohyocholic Acid (sodium salt)
T37846
Taurohyocholic acid (THCA) is a taurine-conjugated form of the porcine-specific primary bile acid hyocholic acid .1THCA inhibits precipitation of cholesterol crystals by stabilizing cholesterol in the liquid-crystalline phase.2It prevents cholestasis and cellular necrosis induced by taurolithocholic acid in isolated rat livers.3THCA levels are increased in the urine of patients with hepatitis B-induced cirrhosis.4
  • $229
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Etozolin HCl
T6913353-90-7
Etozolin HCl is a safe and effective diuretic agent in the treatment of acute cardiac failure. In isolated rings of guinea-pig aorta not responding to acetylcholine, the diuretic dexetozoline did not influence basal vascular tone but inhibited noradrenaline- and histamine-induced contractions. Dexetozoline has a very high bioavailability after oral administration and is fairly lipohilic. The half-life of etozolin is 2.5 h. Dexetozoline accumulates in cirrhosis.
  • $1,520
6-8 weeks
Size
QTY
Paromomycin, sulfate (1:1)
T65387
Paromomycin (Sulfate Salt) is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. Paromomycin in combination with sodium stibogluconate has proven to be effective in African and Indian VL (visceral leishmaniasis) and improves survival in African VL[3]. PS (Paromomycin Sulfate) is effective for elimination of B. coli without hematological side effects[4]. The activity of phosphoglucose isomerase was slightly inhibited by 10(-3) M paromomycin sulfate while those of hexokinase, phosphofructokinase and glucose-6-phosphate dehydrogenase were not inhibited[5]. In addition, with regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-aminohippurate clearance were significantly improved (P less than 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man[6]. Significantly higher frequencies of resistance to paromomycin, kanamycin, neomycin and tobramycin were observed in S. aureus isolates from PS (paromomycin supplemented) birds. Paromomycin supplementation resulted in resistance to aminoglycosides in bacteria of PS turkeys. Co-selection for resistance to other antimicrobial agents was observed in E. coli isolates[7].
    7-10 days
    Inquiry
    Polythiazide
    T34107346-18-9
    Polythiazide (NSC-108161, P-2525) is used to treat fluid retention (edema) caused by a variety of causes, including congestive heart failure, severe liver disease (cirrhosis), kidney disease, or steroid or hormonal medication.
      7-10 days
      Inquiry
      L-Ornithine L-aspartate
      T193993230-94-2
      L-Ornithine L-aspartate (Ornithine Aspartate) lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.
      • $39
      In Stock
      Size
      QTY
      Tauroursodeoxycholic Acid-d4 Sodium Salt
      TMIH-0552
      Tauroursodeoxycholic Acid-d4 Sodium Salt is a deuterated compound of Tauroursodeoxycholic Acid Sodium Salt. Tauroursodeoxycholic Acid Sodium Salt has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
      • $514
      7-10 days
      Size
      QTY
      Tauroursodeoxycholic-2,2,3,4,4-d5 Acid
      TMIJ-01971207294-25-4
      Tauroursodeoxycholic-2,2,3,4,4-d5 Acid is a deuterated compound of Tauroursodeoxycholic Acid. Tauroursodeoxycholic Acid has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
      • Inquiry Price
      20 days
      Size
      QTY
      Invopressin
      T802701488411-60-4
      Invopressin (Compound 42), a vasopressin V1A receptor partial agonist (EC50: 1.0 nM), is utilized in research related to cirrhosis conditions such as bacterial peritonitis, HRS2, and refractory ascites [1].
      • Inquiry Price
      Size
      QTY
      Satavaptan
      T28664185913-78-4
      Satavaptan is a vasopressin V2 receptor antagonist. Satavaptan improves the control of ascites in cirrhosis.
      • $3,170
      10-14 weeks
      Size
      QTY
      Tauroursodeoxycholic-d4 Acid
      TMIJ-01992410279-94-4
      Tauroursodeoxycholic-d4 Acid is a deuterated compound of Tauroursodeoxycholic Acid. Tauroursodeoxycholic Acid has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
      • Inquiry Price
      20 days
      Size
      QTY
      Torsemide
      T141056211-40-6
      Torsemide (AC-4464) is an anilinopyridine sulfonylurea belonging to the class of loop diuretics. Torsemide has a prolonged duration of action compared to other loop diuretics, is extensively protein bound in plasma and has a relatively long half-life.
      • $48
      In Stock
      Size
      QTY
      Taurohyocholic Acid sodium
      T85281117997-17-8
      Taurohyocholic acid (THCA), a taurine-conjugated form of porcine-specific primary bile acid hyocholic acid, inhibits cholesterol crystal precipitation by stabilizing cholesterol in the liquid-crystalline phase and prevents cholestasis and cellular necrosis in isolated rat livers induced by taurolithocholic acid. Additionally, THCA levels rise in the urine of patients with hepatitis B-induced cirrhosis.
      • Inquiry Price
      Size
      QTY
      TAK-044
      T34773157380-72-8
      TAK-044 is an endotheliin receptor antagonist that prevents and reverses the development of carbon tetrachloride induced cirrhosis in rats. TAK-044 showed a protective effect on neuronal activity in vitro hypoxic glucose deprivation model of stroke.
      • $1,520
      Backorder
      Size
      QTY
      BI‑3231
      T734462894848-07-6
      BI‑3231 is a selective and potent inhibitor of hydroxysteroid 17ß-dehydrogenase 13 HSD17B13, inhibiting hHSD17B13 and mHSD17B13.BI-3231 can be used for the study of alcohol-associated liver injury, fibrosis and cirrhosis.
      • $129
      In Stock
      Size
      QTY
      BMS-986339
      T731552477873-64-4
      BMS-986339 is an orally active, potent FXR agonist that interacts via H-bond formation with the His298 and ASN287 residues. It is utilized in research focused on primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH) for its anti-fibrosis properties.
      • $2,270
      10-14 weeks
      Size
      QTY